Kymera Therapeutics, Inc. (KYMR)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Kymera Therapeutics’ preliminary results for the third fiscal quarter of 2026, reported October 29, 2026, showed EPS of -$1.32 trailing the -$1.26 estimate by -$0.06 as the company posted a wider year-over-year loss. Net income came in at -about $132.0 million, a -61% change year over year and down from roughly -$82.2 million a year ago, while operating income was -around $147.2 million. The period reflected ongoing spend across its drug discovery and development efforts, including targeted programs such as IRAK4, with no segment-level revenue detail provided in the preliminary release. Operating cash flow was negative at about -$77.9 million, consistent with the company funding R&D and operations. For year-over-year context on per-share results, EPS deteriorated -47% from -$0.90 a year ago. Consensus for the next period calls for EPS of -$1.28 on revenue of $1.2 million.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a NASDAQ-listed biotechnology company that develops small molecule therapeutics designed to harness the body's protein degradation system to eliminate disease-causing proteins. In healthcare, its work centers on drug discovery and development, and it recorded $39.2 million of revenue in FY2025.
Today's Snapshot
KYMR closed slightly lower at 121.13, while its sector was weaker. Shares changed hands at about two-thirds of its usual level.
Trading Volume
Below 10d avg (923.9K)
646.5K
vs S&P 500 Today
Inline with Market
-0.06%
Updated: November 18, 2026 at 21:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$100.91 - $126.38Buy
- RSI (14)47.36Neutral
- Stochastic %K (14, 3, 3)23.06Neutral
- MACD Level (12, 26)2.86Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.